

2017 EMERGING THERAPIES FOR PBC, NASH ESLD AND HCC SEMINAR SERIES

San Diego, CA – May 13, 2017

Conference Location **San Diego Marriott - Del Mar** **Phone: (858)-523-1700**
119166 El Camino Real,
San Diego, California, 92130 <http://www.marriott.com/hotels/travel/sandm-san-diego-marriott-del-mar>

Parking at the Conference A reduced parking rate of \$10 for the day has been arranged for all seminar participants. Please bring your ticket to the Seminar Registration Desk for validation.

Driving Directions

From Interstate 5 - Northbound - Take Carmel Valley Road Exit, turn right, turn left onto El Camino Real. Hotel will be on the right side.

From Interstate 5 - Southbound - Take Carmel Valley Road Exit, turn left, turn left again onto El Camino Real. Hotel will be on the right side

Seminar Agenda and Syllabus Information

Registration begin at **10:30 a.m.** in the **Rancho Santa Fe Ballroom**. Please check signage for any last minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.

10:30 am	Registration, Continental Breakfast & View Exhibits
11:00am	Welcome and Pre-Test
11:15 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant <ul style="list-style-type: none"> • Treatment of cirrhosis and hepatic encephalopathy • Management of esophageal varices • Treatment of ascites, edema and hepatorenal syndrome • Liver Transplantation <ul style="list-style-type: none"> ○ Listing Criteria and MELD Exceptions
12:05 pm	Hepatocellular Carcinoma <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Chemotherapies
12:40 pm	Hepatocellular Carcinoma: New Locoregional and Systemic Treatment Options <ul style="list-style-type: none"> • Current treatments with Sorafenib • New chemotherapy treatments in development
1:15pm	Lunch & View Exhibits
2:00 pm	Primary Sclerosing Cholangitis (PBS) <ul style="list-style-type: none"> • Epidemiology • Ursodiol and Antibiotic Treatments • Predicting Outcomes and Improving Survival
2:45 pm	New Treatments for Primary Biliary Cholangitis (PBC)

	<ul style="list-style-type: none"> • Causes and Markers of PBC • Treatment Management • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
3:25 pm	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology and Demographics • Diagnosis • Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Causing Adult Fatty Liver • Conventional treatments
4:00 pm	Break & View Exhibits
4:15 pm	NASH Treatments in Development <ul style="list-style-type: none"> • Life Style Changes • Obeticholic Acid • Elafibranor (GTR505)
5:00 pm	Case Presentations <ul style="list-style-type: none"> • HCC • PBC with inadequate response to Ursodiol • NASH Diagnosis and Treatment
5:40 pm	Summary and Post-test
6:00 pm	Adjourn

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Information

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.2 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-16-878. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.

**Your Seminar
Faculty**



CATHERINE FRENETTE, MD

Dr. Carrie Frenette is the Medical Director of Liver Transplantation in the Department of Organ Transplantation at Scripps Green Hospital, San Diego, CA. She also serves as the Director, Hepatocellular Carcinoma Program for Scripps. She received his bachelor's degree in Biology from Loyola University in Chicago, IL and her medical degree from Rush Medical College, also in Chicago. Dr. Frenette is widely published in many peer-reviewed journals.

Dr. Frenette is active in many professional societies including: the American Gastroenterology Association; American College of Gastroenterology; European Association for the Study of the Liver; The Transplantation Society; the International Liver Cancer Association and the American Liver Foundation.



ROHIT LOOMBA MD, MHSci

Rohit Loomba M.D., MHSci, is Professor of Medicine (with tenure) in the Division of Gastroenterology, and Adjunct Professor in the Division of Epidemiology at University of California at San Diego (UCSD).

He is an internationally recognized expert in translational research and innovative clinical trial design in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), and non-invasive assessment of steatosis and fibrosis using advanced imaging modalities. Dr. Loomba is the founding director of the NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, clinical trial design epidemiology, imaging end-points, and integrated OMICs.



HEATHER PATTON, MD, AGAF

Dr. Heather Patton is a transplant Hepatologist with Southern California Permanente Medical Group where she provides care to over 600,000 Kaiser Permanente healthcare members in San Diego County. She completed her bachelor's degree at Oberlin College, medical school at the University of Michigan, Internal Medicine residency at Northwestern University, and Gastroenterology and Hepatology fellowship at Scripps clinic and UCSD. Dr. Patton is board certified in Gastroenterology and Transplant Hepatology and was recognized as a Fellow of the American Gastroenterological Association in 2014.

Before joining SCPMG, Dr. Patton was an Associate Professor of Medicine at UCSD where she was a faculty member for nine years. While on faculty at UCSD Dr. Patton established the transplant hepatology fellowship training program there. She has been published in several peer-review journals for work in complications of cirrhosis, acute liver failure, and nonalcoholic fatty liver.
